ASCO Roundup: Looking For The Future Of Cancer Research

As the American Society of Clinical Oncology annual meeting drew to a close, industry execs discussed staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.

Asco 2024 Sign

Biopharma industry executives talk about what it takes to stay competitive in the most active area of drug development.

For oncology leaders, that means matching unmet need with transformational opportunities, balancing multiple modalities and staying nimble – as well...

More from Business Strategy

More from Scrip